| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Mar, 2025 | Mar, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -11,980 | -7,060 | 0 | 0 | 0 |
| Net Income Growth | -69.69% | unch | unch | unch | unch |
Mira Pharmaceuticals Inc (MIRA)
1.1800 -0.0500 (-4.07%) 15:41 ET [NASDAQ]
1.1800 x 7 1.2000 x 1
Realtime by (Cboe BZX)
1.1800 x 7 1.2000 x 1
Realtime 1.1800 -0.0500 (-4.07%) 08:43 ET
for Tue, Mar 25th, 2025
MIRA Pharmaceuticals Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA Pharmaceuticals Inc. is based in Baltimore, Maryland.
Fiscal Year End Date: 12/31